Insider Sell: Personalis
6:16AM ET 1/20/2022 MT NewswiresJohn Stephen West, Director, President and CEO, on January 18, 2022, sold 99,987 shares in Personalis (PSNL) for $1,126,405. Following the Form 4 filing...
Quotes Snapshot > PSNL
Personalis Inc PSNL:NASDAQ
Last Price$10.19NASDAQ Previous Close - Last Trade as of 3:57PM ET 1/26/22
Today's Change-0.16(1.55%)
Bid (Size)N/A (N/A)
Ask (Size)N/A (N/A)
Day Low / High$10.08 - 11.43
Volume613.5 K
Read more news Recent News
Personalis Shares Climb Higher in Afternoon Trading Following Preliminary Revenue Report
1:03PM ET 1/07/2022 MT NewswiresPersonalis (PSNL) shares are up more than 8% in early Friday afternoon trading after the cancer genomics company reported preliminary Q4 and full-year 2021...
Personalis Expects $20.7 Million in Revenue for Q4'21
4:13PM ET 1/06/2022 MT NewswiresPersonalis (PSNL) reported preliminary results Thursday and anticipates fourth-quarter revenue to be roughly $20.7 million. Revenue for the year ending...
View all Commentary and Analysis
Personalis' (PSNL) CEO John West on Q3 2021 Results - Earnings Call Transcript
2:03PM ET 11/04/2021 Seeking AlphaPersonalis (PSNL) Investor Presentation - Slideshow
4:24PM ET 8/21/2021 Seeking AlphaPersonalis' (PSNL) CEO John West on Q2 2021 Results - Earnings Call Transcript
11:57PM ET 8/04/2021 Seeking AlphaPersonalis: Market-Leading Immuno-Oncology Platform Drives Consistent Long-Term Growth
12:49AM ET 6/21/2021 Seeking AlphaCompany Profile
Business DescriptionPersonalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA. View company web site for more details
| Address | 1330 O'Brien Drive Menlo Park, California 94025 |
| Phone | +1.650.752.1300 |
| Number of Employees | 139 |
| President, Chief Executive Officer & Director | John S. West |
| Chief Financial Officer | Aaron Tachibana |
| Chief Scientific Officer | Richard O. Chen |
| Vice President-Immunology, Research & Development | Xavier Paliard |
Company Highlights
| Price Open | $10.87 |
| Previous Close | $10.19 |
| 52 Week Range | $9.04 - 48.01 |
| Market Capitalization | $456.3 M |
| Shares Outstanding | 44.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/24/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.37 |
| Beta vs. S&P 500 | N/A |
| Revenue | $37.8 M |
| Net Profit Margin | -68.68% |
| Return on Equity | -19.34% |
Analyst Ratings as of 01/07/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |